Business Insider

Axonics Modulation Technologies (AXNX) was downgraded to a Hold Rating at Wolfe Research

Axonics Modulation Technologies (AXNX – Research Report) received a Hold rating and price target from Wolfe Research analyst Michael Polark yesterday. The company’s shares closed yesterday at $69.36.
Business Insider

Axonics Modulation Technologies (AXNX) Receives a Hold from RBC Capital

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $71.00. The company’s ...
AOL

Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Misses Revenue Estimates

Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $2.67 per share a year ago.
AOL

The Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) First-Quarter Results Are Out And Analysts Have Published New Forecasts

As you might know, Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) just kicked off its latest first-quarter results with some very strong numbers. Sales crushed expectations at US$26m, beating ...
Business Wire

Axonics Granted Four U.S. Patents Related to its Implantable Sacral Neuromodulation Technology

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, ...
Seeking Alpha

First Look | Axonics Modulation Files To Raise $86 Million In IPO

Axonics Modulation Technologies (AXNX) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.The firm develops and commercializes minimally ...